Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

MPD-RC 101 prospective study of reduced intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, Prchal JT, Najfeld V, Orazi A, Weinberg RS, Miller C, Barosi G, Silverman LR, Prosperini G, Marchioli R, Hoffman R.

Blood. 2014 Jun 24. pii: blood-2014-04-572545. [Epub ahead of print]

PMID:
24963042
[PubMed - as supplied by publisher]
2.

The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.

Satlin MJ, Soave R, Racanelli AC, Shore TB, van Besien K, Jenkins SG, Walsh TJ.

Leuk Lymphoma. 2014 Mar 24. [Epub ahead of print]

PMID:
24559288
[PubMed - as supplied by publisher]
3.

Human rhinovirus infections of the lower respiratory tract in hematopoietic stem cell transplant recipients.

Jacobs SE, Soave R, Shore TB, Satlin MJ, Schuetz AN, Magro C, Jenkins SG, Walsh TJ.

Transpl Infect Dis. 2013 Oct;15(5):474-86. doi: 10.1111/tid.12111. Epub 2013 Jul 25.

PMID:
23890179
[PubMed - in process]
4.

Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.

Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K, Xiang Z, Ely S, Skerret D, Chen-Kiang S, Coleman M, Lane ME.

Clin Cancer Res. 2013 Mar 15;19(6):1534-46. doi: 10.1158/1078-0432.CCR-12-1429. Epub 2013 Jan 28.

PMID:
23357980
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A prospective evaluation of changes in brain structure and cognitive functions in adult stem cell transplant recipients.

Correa DD, Root JC, Baser R, Moore D, Peck KK, Lis E, Shore TB, Thaler HT, Jakubowski A, Relkin N.

Brain Imaging Behav. 2013 Dec;7(4):478-90. doi: 10.1007/s11682-013-9221-8.

PMID:
23329358
[PubMed - in process]
6.

Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies.

Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, Feldman EJ, Roboz GJ, Shore TB, Helfgott DC, Soave R, Kreiswirth BN, Walsh TJ.

Leuk Lymphoma. 2013 Apr;54(4):799-806. doi: 10.3109/10428194.2012.723210. Epub 2012 Sep 14.

PMID:
22916826
[PubMed - indexed for MEDLINE]
7.

Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity.

Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP, Gergis U.

Am J Hematol. 2012 Apr;87(4):433-5. doi: 10.1002/ajh.23108. Epub 2012 Feb 24. No abstract available.

PMID:
22367772
[PubMed - indexed for MEDLINE]
8.

Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.

Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, Shore TB, Durrant S, Szer J, Chen MG, Lizambri R, Waller EK.

Bone Marrow Transplant. 2012 Oct;47(10):1350-5. doi: 10.1038/bmt.2011.261. Epub 2012 Feb 13.

PMID:
22327131
[PubMed - indexed for MEDLINE]
9.

Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.

Elstrom RL, Andemariam B, Martin P, Ruan J, Shore TB, Coleman M, Leonard JP, Furman RR.

Leuk Lymphoma. 2012 Aug;53(8):1469-73. doi: 10.3109/10428194.2012.656629.

PMID:
22263572
[PubMed - indexed for MEDLINE]
10.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; Blood and Marrow Transplant Clinical Trials Network.

Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.

PMID:
21527516
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors.

Stiff PJ, Bensinger W, Abidi MH, Gingrich R, Artz AS, Nademanee A, Hansen KS, Sobczak C, Cutler C, Bolwell B, Shore TB, Lazarus HM, Yeager AM, Lovelace W, Guo M, Dreiling L.

Biol Blood Marrow Transplant. 2009 Jul;15(7):827-34. doi: 10.1016/j.bbmt.2009.03.015.

PMID:
19539214
[PubMed - indexed for MEDLINE]
12.

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP.

Ann Oncol. 2008 Jul;19(7):1327-30. doi: 10.1093/annonc/mdn045. Epub 2008 Mar 17.

PMID:
18349031
[PubMed - indexed for MEDLINE]
Free Article
13.

Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant.

Schuster MW, Shore TB, Harpel JG, Greenberg J, Jalilizeinali B, Possley S, Gerwien RW, Hahne W, Halvorsen YD.

Support Care Cancer. 2008 May;16(5):477-83. Epub 2007 Aug 21.

PMID:
17710442
[PubMed - indexed for MEDLINE]
14.

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.

Mones JV, Coleman M, Kostakoglu L, Furman RR, Chadburn A, Shore TB, Muss D, Stewart P, Kroll S, Vallabhajosula S, Goldsmith SJ, Leonard JP.

Leuk Lymphoma. 2007 Feb;48(2):342-8.

PMID:
17325895
[PubMed - indexed for MEDLINE]
15.

A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.

Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, Shore TB, Walker IR, Browett P, Messner HA, Panzarella T, Lipton JH; Canadian Bone Marrow Transplant Group.

Blood. 2002 Sep 1;100(5):1525-31.

PMID:
12176866
[PubMed - indexed for MEDLINE]
Free Article
16.

Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.

Bow EJ, Gallant G, Williams GJ, Woloschuk D, Shore TB, Rubinger M, Schacter BA.

Cancer. 1998 Oct 1;83(7):1344-54.

PMID:
9762935
[PubMed - indexed for MEDLINE]
17.

Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults.

Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B.

J Clin Oncol. 1997 Jun;15(6):2254-61.

PMID:
9196138
[PubMed - indexed for MEDLINE]
18.

Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.

Bow EJ, Sutherland JA, Kilpatrick MG, Williams GJ, Clinch JJ, Shore TB, Rubinger M, Schacter BA.

J Clin Oncol. 1996 Apr;14(4):1345-52.

PMID:
8648393
[PubMed - indexed for MEDLINE]
19.

Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.

Shepherd JD, Shore TB, Reece DE, Barnett MJ, Klingemann HG, Buskard NA, Phillips GL.

Bone Marrow Transplant. 1988 Nov;3(6):553-8.

PMID:
3063323
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk